

# West Virginia Medicaid Drug Utilization Review Board Minutes

May 22, 2019

The West Virginia Medicaid Drug utilization Review (DUR) Board meeting was called to order with the following in attendance:

## **Members:**

Lester Labus, MD, Chair  
K.C. Lovin, PA-C, Vice Chair  
Michael Ballow, PharmD, (phone in)  
C.K. Babcock, PharmD  
Chris Booth, PharmD  
Scott Brown, RPh (phone in)  
Myra Chiang, MD  
Ernest Miller, DO  
Mary Nemeth-Pyles, MSN, RN, CS  
Christopher Terpening, PharmD, PhD  
John Vanin, MD

## **Members Absent:**

Kate Forman, PharmD  
Michael Lonsinger, PharmD

## **DHHR/BMS Staff:**

Vicki Cunningham, RPh, Director of Pharmacy Services  
Brian Thompson, MS, PharmD, DUR Coordinator  
Lori Moles, RPh, Staff Pharmacist  
Bill Hopkins, Pharmacy Operations Manager  
Doug Sorvig, Analyst

## **Contract Staff:**

Angela Wowczuk, PharmD, Rational Drug Therapy Program (RDTPP)  
Alesha Heil, PharmD, SEMP  
Rob Stanton, PharmD, Marshall University  
Kim Broedel-Zaugg, RPh, PhD, Marshall University  
John Willis, Marshall University  
Eric Sears, RPh, DXC  
Brent Breeding, RPh, Change Healthcare  
Jeff Barken, MD, Change Healthcare (phone in)

### **I. INTRODUCTIONS**

- a. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:10pm EDT. The DUR Board and attendees introduced themselves.

### **II. APPROVAL OF MINUTES FROM FEBRUARY 27, 2019 DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. **OLD BUSINESS**

- a. None

IV. **NEW BUSINESS**

a. **Speakers**

- |                   |        |          |
|-------------------|--------|----------|
| i. Kayleen Daly   | J & J  | Spravato |
| ii. David Griffin | Takeda | Takhyzro |
| iii. Ahmad Nesser | Amgen  | Repatha  |

b. **Updates from April 24, 2019 P & T Committee Meeting**

- i. Mr. Breeding presented the updates from the April 24, 2019 P & T meeting for board review. No changes were requested.

c. **PDL Prior Authorization Criteria.** Attachment A

- i. **Lovaza:** Approved with amendments (removed requirement for niacin & fenofibrate)
- ii. **CGM Devices (Dexcom G6, Freestyle Libre):** Approved with amendments (added exception for patients under the age of 18 and removed A1C requirement).
- iii. **Omnipod:** Approved with amendments (added endocrinologist consult and removed A1C requirement)
- iv. **PCSK9 Inhibitors:** Approved as presented.
- v. **Qbrexza:** Approved as presented.
- vi. **Spravato:** Approved with amendments (changed prescriber requirement to REMS-certified, added psychiatrist-required diagnosis of TRD, and reduced required antidepressant trials to three).
- vii. **HAE agents (Takhyzro):** Approved as presented.
- viii. **Xifaxan:** Approved as presented (removed requirement for neomycin and metronidazole)

V. **REPORTS**

- a. **DXC Quarterly Report:** Mr. Sears presented an overview of the 2019 First Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the First Quarter of 2019. Attachment C
- c. **Marshall University:** Dr. Stanton reported on the progress of Retro DUR, the Pharmacy Lock-in program, and ideas for future interventions.

VI. **OTHER BUSINESS**

- a. Dr. Babcock requested that the P & T Committee consider adding Suboxone tablets as a Preferred agent.
- b. Dr. Thompson announced that Pharmacy Director Vicki Cunningham will be retiring in June.

VII. **NEXT MEETING AND ADJOURNMENT**

- VIII. a. A motion to adjourn the meeting was made, seconded, and passed.
- b. The meeting concluded at 6:20pm EDT.
- c. The next meeting will be September 25, 2019 from 4:00pm to 6:00pm and located at WVDHHR.